文献速递糖尿病肥胖与代谢综合征

恩格列净对2型糖尿病合并动脉粥样硬化性心血管疾病患者首发及复发性临床事件的影响:EMPA-REG OUTCOME试验二次分析

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-01-01

EMPA-REG OUTCOME试验的二次分析评估恩格列净对2型糖尿病合并动脉粥样硬化性心血管疾病患者总心血管事件及住院的影响。

核心结论

  • 在2型糖尿病合并动脉粥样硬化性心血管疾病患者中,恩格列净降低了心血管并发症的总负担和全因住院。

研究设计与样本

  • EMPA-REG OUTCOME试验的二次分析,随机、双盲、非劣效性试验,纳入年龄≥18岁的2型糖尿病合并动脉粥样硬化性心血管疾病患者,2010年8月至2015年4月进行。
  • 共7020例患者随机分配(1:1:1)至恩格列净10mg(n=2345)、恩格列净25mg(n=2342)或安慰剂(n=2333)。
  • 主要结局为主要不良心血管事件复合终点(心血管死亡、非致死性卒中或非致死性心肌梗死)。
  • 预设分析汇总恩格列净组与安慰剂组对总(首发+复发)事件的影响,采用负二项回归等统计模型。

临床怎么用

  • 对于2型糖尿病合并动脉粥样硬化性心血管疾病患者,恩格列净可考虑用于减少心血管事件总负担和住院风险。
  • 恩格列净对总事件(首发+复发)的获益可能大于仅分析首发事件时的观察结果。

局限性

  • 本分析为EMPA-REG OUTCOME试验的二次分析,部分分析为事后分析。
  • 研究仅纳入合并动脉粥样硬化性心血管疾病的2型糖尿病患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in the EMPA-REG OUTCOME trial. METHODS: The EMPA-REG OUTCOME trial was a randomised, double-blind, non-inferiority trial of patients (aged ≥18 years) with type 2 diabetes and atherosclerotic cardiovascular disease done between August, 2010, and April, 2015. Participants were randomly assigned (1:1:1) to empagliflozin 10 mg or 25 mg, or placebo. The primary outcome was major adverse cardiovascular events: a composite of cardiovascular death, non-fatal stroke, or non-fatal myocardial infarction. As prespecified, the effects of pooled empagliflozin versus placebo were assessed on total (first plus recurrent) events of major adverse cardiovascular events, fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, and admission to hospital for heart failure. We also did post-hoc analyses on additional cardiovascular and admission to hospital outcomes. We used statistical models that preserve randomisation and account for correlation of recurrent events, including negative binomial regression, as prespecified for the primary analyses. The EMPA-REG OUTCOME trial is registered with ClinicalTrials.gov, NCT01131676, and is closed to accrual. FINDINGS: In the EMPA-REG OUTCOME trial, 7020 patients were randomly assigned and treated with empagliflozin 10 mg (n=2345), empagliflozin 25 mg (n=2342), or placebo (n=2333) and followed up for a median of 3·2 years (IQR 2·2 to 3·6) in the pooled empagliflozin group and 3·1 years (2·2 to 3·5) in the placebo group. Analysing total (first plus recurrent) events, empagliflozin versus placebo reduced the risk of major adverse cardiovascular events (rate ratio [RR] 0·78 [95% CI 0·67 to 0·91]; p=0·0020; 12·88 [95% CI 3·74 to 22·02] events prevented per 1000 patient-years); fatal or non-fatal myocardial infarction (0·79 [0·62 to 0·998]; p=0·049; 4·97 [-0·68 to 10·61] events prevented per 1000 patient-years); the composite of fatal or non-fatal myocardial infarction, or coronary revascularisation (0·80 [0·67 to 0·95]; p=0·012; 11·65 [1·25 to 22·05] events prevented per 1000 patient-years); admission to hospital for heart failure (0·58 [0·42 to 0·81]; p=0·0012; 9·67 [3·07 to 16·28] events prevented per 1000 patient-years); and all-cause admission to hospital (0·83 [0·76 to 0·91]; p<0·0001; 50·41 [26·20 to 74·63] events prevented per 1000 patient-years). For outcomes significantly reduced with empagliflozin, risk reductions were numerically larger for total events than for first events. Total fatal or non-fatal stroke was not significantly different between treatment groups (RR 1·10 [95% CI 0·82 to 1·49]; p=0·52). INTERPRETATION: Empagliflozin reduced the total burden of cardiovascular complications and all-cause admission to hospital in patients with type 2 diabetes and atherosclerotic cardiovascular disease. FUNDING: The Boehringer Ingelheim and Lilly Alliance.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. McGuire DK, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol. 2020. PMID: 33217335. doi:10.1016/S2213-8587(20)30344-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。